NHS Set to Take 12 Years to Roll Out Mounjaro, the New Weight-Loss Drug
The NHS is about to introduce a groundbreaking weight-loss drug, Mounjaro (tirzepatide), to help tackle the growing obesity crisis in the UK. However, despite its potential to transform lives, it will take up to 12 years for the drug to be widely available to those in need. This slow rollout is due to concerns over NHS capacity and the potential strain on services, particularly GPs, who would be required to provide the ongoing support for patients using the drug.
Mounjaro, developed by Eli Lilly, has shown impressive results in clinical trials, with patients losing an average of 20% of their body weight after using the drug for 72 weeks. This new class of medications works by making users feel fuller, thereby reducing their appetite and helping with weight loss. The drug is expected to be offered to patients with a body mass index (BMI) of over 35 and at least one obesity-related health condition, such as diabetes, high blood pressure, or heart disease. This could benefit up to 3.4 million people in the UK who are living with severe obesity.
Also Read:- Australia's Dominance in Day-Night Tests: A Statistical Breakdown
- Isaiah Evans Shines in Duke's Hard-Fought Victory Over Auburn in ACC-SEC Challenge
However, the National Institute for Health and Care Excellence (NICE) has recommended a phased rollout of Mounjaro, starting in March. Initially, the drug will be available only to patients under the care of specialist weight management services, which limits its accessibility. This slow start is due to concerns that the NHS could be overwhelmed if the drug were rolled out too quickly. GPs and other healthcare services will need time to adjust and implement new systems to support patients on the medication. This means that only around 220,000 people will be able to access the drug over the next three years, a far cry from the millions who could benefit from it.
The phased rollout is a response to a request from NHS England, which asked for more time to set up the necessary infrastructure and train healthcare professionals. The concern is that launching the drug too quickly could further strain an already overstretched NHS, affecting the quality of care for other essential services. NHS England has highlighted that treating obesity-related conditions already costs the NHS around £11.4 billion a year, so introducing Mounjaro could ultimately help reduce long-term healthcare costs.
While many patient groups have expressed disappointment with the slow rollout, the rationale behind the decision is to ensure that the delivery of Mounjaro is done effectively and sustainably. Health experts warn that the drug is not a "magic bullet" and should be seen as part of a broader strategy that includes diet, exercise, and behavioral changes. Dr. Kath McCullough, NHS England’s national specialty adviser for obesity, stressed that weight-loss medications should be combined with professional support to achieve lasting success.
As the NHS prepares to introduce Mounjaro, there is a sense of cautious optimism. This new medication has the potential to significantly reduce the risk of obesity-related diseases such as heart disease and stroke, offering hope for many who have struggled with their weight. But the road to widespread access will be long, and many will have to wait.
Read More:
0 Comments